JP2017522312A5 - - Google Patents

Download PDF

Info

Publication number
JP2017522312A5
JP2017522312A5 JP2017502194A JP2017502194A JP2017522312A5 JP 2017522312 A5 JP2017522312 A5 JP 2017522312A5 JP 2017502194 A JP2017502194 A JP 2017502194A JP 2017502194 A JP2017502194 A JP 2017502194A JP 2017522312 A5 JP2017522312 A5 JP 2017522312A5
Authority
JP
Japan
Prior art keywords
immunogenic composition
doses
antigen
combination
combination according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017502194A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522312A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/040453 external-priority patent/WO2016011083A1/en
Publication of JP2017522312A publication Critical patent/JP2017522312A/ja
Publication of JP2017522312A5 publication Critical patent/JP2017522312A5/ja
Pending legal-status Critical Current

Links

JP2017502194A 2014-07-15 2015-07-14 Ｔｌｒ４アゴニストアジュバント及びレンチウイルスベクターを用いたプライム・ブーストレジメン Pending JP2017522312A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462024797P 2014-07-15 2014-07-15
US201462024792P 2014-07-15 2014-07-15
US62/024,792 2014-07-15
US62/024,797 2014-07-15
PCT/US2015/040453 WO2016011083A1 (en) 2014-07-15 2015-07-14 Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector

Publications (2)

Publication Number Publication Date
JP2017522312A JP2017522312A (ja) 2017-08-10
JP2017522312A5 true JP2017522312A5 (enExample) 2018-08-23

Family

ID=53776968

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017502194A Pending JP2017522312A (ja) 2014-07-15 2015-07-14 Ｔｌｒ４アゴニストアジュバント及びレンチウイルスベクターを用いたプライム・ブーストレジメン

Country Status (8)

Country Link
US (1) US20170196954A1 (enExample)
EP (1) EP3169352A1 (enExample)
JP (1) JP2017522312A (enExample)
KR (1) KR20170032373A (enExample)
AU (1) AU2015289773A1 (enExample)
CA (1) CA2955015A1 (enExample)
MX (1) MX2017000630A (enExample)
WO (1) WO2016011083A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201808457PA (en) 2016-04-15 2018-10-30 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
AU2017248830B2 (en) 2016-04-15 2023-03-09 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
WO2018148180A2 (en) * 2017-02-07 2018-08-16 Immune Design Corp. Materials and methods for identifying and treating cancer patients
FI3596116T3 (fi) 2017-03-16 2023-11-09 Alpine Immune Sciences Inc Immunomodulatorisia pd-l1-varianttiproteiineja ja niiden käyttöjä
MX2019010887A (es) 2017-03-16 2019-10-15 Alpine Immune Sciences Inc Proteinas inmunomoduladoras de cb80 variante y usos de estas.
JP2020511144A (ja) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用
EP3694870A1 (en) 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
JP7282760B2 (ja) 2017-10-18 2023-05-29 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
US20210046130A1 (en) * 2018-01-24 2021-02-18 Virogin Biotech Canada Ltd Recombinant viral vaccines
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
JP2022500034A (ja) * 2018-09-10 2022-01-04 トルク セラピューティクス， インコーポレイテッド 抗原特異的ｔリンパ球ならびに抗原特異的ｔリンパ球を作製および使用する方法
CN113544144A (zh) 2018-09-19 2021-10-22 高山免疫科学股份有限公司 变体cd80融合蛋白和相关构建体的方法和用途
EP3628735A1 (en) 2018-09-25 2020-04-01 Centre National De La Recherche Scientifique Antisense rna targeting pmp22 for the treatment of charcot-marie-tooth 1a disease
CN113727998A (zh) 2018-11-30 2021-11-30 高山免疫科学股份有限公司 Cd86变体免疫调节蛋白及其用途
WO2020131656A1 (en) * 2018-12-17 2020-06-25 Immune Design Corp. Pathogen-associated molecular pattern molecules and rna immunogenic compositions and methods of using the compositions for treating cancer
BR112021020447A2 (pt) 2019-04-17 2022-05-17 Alpine Immune Sciences Inc Métodos e usos de proteínas de fusão de ligante icos variante (icosl)
US12202882B2 (en) 2020-05-08 2025-01-21 Alpine Immune Sciences, Inc. APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
AU2022269139A1 (en) 2021-05-07 2023-11-16 Alpine Immune Sciences, Inc. Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
US20250243260A1 (en) 2022-03-07 2025-07-31 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies and related methods and uses
IL319997A (en) 2022-10-04 2025-06-01 Alpine Immune Sciences Inc Mutated taci-fc fusion proteins for use in the treatment of autoantibody-mediated diseases

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4569794A (en) 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5352449A (en) 1986-05-30 1994-10-04 Cambridge Biotech Corporation Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5443964A (en) 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
ATE112314T1 (de) 1988-05-17 1994-10-15 Lubrizol Genetics Inc Pflanzliches ubiquitinpromotorsystem.
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
EP0584266B1 (en) 1991-05-06 2003-09-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
US5273965A (en) 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
MX9304089A (es) 1992-07-08 1994-01-31 Schering Corp Uso de gm-csf como una vacuna adyuvante.
JPH07509133A (ja) 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤
US5786148A (en) 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
DE9319879U1 (de) 1993-12-23 1994-03-17 Ems-Inventa AG, Zürich Sequentiell Coextrudierte Kühlflüssigkeitsleitung
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
WO1996009380A1 (en) 1994-09-23 1996-03-28 The University Of British Columbia Method of enhancing expression of mhc class i molecules bearing endogenous peptides
ATE197765T1 (de) 1994-10-03 2000-12-15 Us Gov Health & Human Serv Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
US5955306A (en) 1996-09-17 1999-09-21 Millenium Pharmaceuticals, Inc. Genes encoding proteins that interact with the tub protein
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
EP0961830A1 (en) 1997-01-29 1999-12-08 Neurosearch A/S EXPRESSION VECTORS AND METHODS FOR $i(IN VIVO) EXPRESSION OF THERAPEUTIC POLYPEPTIDES
CA2281954A1 (en) 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
ES2356342T3 (es) 1998-01-05 2011-04-07 The University Of Washington Mejora de transporte utilizando agentes de alteración de membrana.
BR9907691B1 (pt) 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
JP2002511266A (ja) 1998-04-15 2002-04-16 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 腫瘍関連核酸及びその使用
GB2337755B (en) 1998-05-29 2003-10-29 Secr Defence Virus vaccine
TR200100916T2 (enExample) 1998-07-14 2002-06-21 Corixa@@Corporation
CN1348463A (zh) 1998-08-07 2002-05-08 华盛顿大学 免疫学单纯疱疹病毒抗原及其使用方法
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
US6596535B1 (en) 1999-08-09 2003-07-22 Targeted Genetics Corporation Metabolically activated recombinant viral vectors and methods for the preparation and use
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
WO2002087541A1 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
DE60235041D1 (de) 2001-11-30 2010-02-25 Us Gov Health & Human Serv Und ihre verwendung
EP1819823A2 (en) 2004-12-01 2007-08-22 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
EP2468300B1 (en) 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8563523B2 (en) 2007-09-07 2013-10-22 University Of Georgia Research Foundation, Inc. Synthetic lipid A derivative
LT2222861T (lt) 2007-12-11 2018-03-26 The University Of North Carolina At Chapel Hill Retrovirusiniai vektoriai modifikuoti polipurino atkarpa
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
EP2456786B2 (en) 2009-07-24 2017-04-19 Immune Design Corp Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
NZ616304A (en) * 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
AU2013237900B2 (en) * 2012-03-30 2017-07-27 Immune Design Corp. Lentiviral vector particles having improved transduction efficiency for cells expressing DC- SIGN
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein

Similar Documents

Publication Publication Date Title
US20190032064A1 (en) Personalized Delivery Vector-Based Immunotherapy and Uses Thereof
JP6921750B2 (ja) ペプチドミニ遺伝子発現系を含むリステリアベースの組成物およびその使用方法
CA3212964A1 (en) Tumor neoantigenic peptides
TW201639594A (zh) 利用重組李斯特菌菌株之組合療法
Xiao et al. Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice
JP2018515588A (ja) 個別化送達ベクターに基づく免疫療法とその使用
Dai et al. PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines
RU2013103335A (ru) Конструкции гомодимерных белков
Jemon et al. An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy
JP7384896B2 (ja) 主要組織適合遺伝子複合（ｍｈｃ）クラスｉｉ－発現癌細胞ワクチン、及び統合免疫応答を生じさせるための使用方法
US20230293650A1 (en) Individualized therapeutic anticancer vaccine
Neukirch et al. Adenovirus based virus-like-vaccines targeting endogenous retroviruses can eliminate growing colorectal cancers in mice
Li et al. Antigen-clustered nanovaccine achieves long-term tumor remission by promoting B/CD 4 T cell crosstalk
Wang et al. The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC‐205/CD205 receptor on dendritic cells
JP2022071130A (ja) ワクチンとして使用するためのエキソソームアンカータンパク質を発現するヌクレオチド配列
WO2018058489A1 (zh) Cacna1h衍生的肿瘤抗原多肽及其应用
Kim et al. Single chain MHC I trimer-based DNA vaccines for protection against Listeria monocytogenes infection
Luo et al. Emerging strategies for advancing peptide vaccines
Lowe et al. Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phase
US20180036400A1 (en) Double engineered hiv-1 envelopes
WO2026077941A1 (en) Lentiviral vectors targeting kras neoepitopes for cancer immunotherapy
AU2015236147A1 (en) Mosaic HIV-1 sequences and uses thereof
CN108025044A (zh) 免疫原性降钙素原前体肽
CA2983259A1 (en) Swarm immunization with envelopes from ch505
WO2007059030A2 (en) Llo-encoding dna/nucleic acid vaccines and methods comprising same